JP2023545983A5 - - Google Patents
Info
- Publication number
- JP2023545983A5 JP2023545983A5 JP2023520379A JP2023520379A JP2023545983A5 JP 2023545983 A5 JP2023545983 A5 JP 2023545983A5 JP 2023520379 A JP2023520379 A JP 2023520379A JP 2023520379 A JP2023520379 A JP 2023520379A JP 2023545983 A5 JP2023545983 A5 JP 2023545983A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063088879P | 2020-10-07 | 2020-10-07 | |
| US63/088,879 | 2020-10-07 | ||
| PCT/US2021/071718 WO2022076987A1 (en) | 2020-10-07 | 2021-10-05 | Bispecific antibody treatment of lymphoid malignant neoplasm conditions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023545983A JP2023545983A (ja) | 2023-11-01 |
| JPWO2022076987A5 JPWO2022076987A5 (https=) | 2024-10-10 |
| JP2023545983A5 true JP2023545983A5 (https=) | 2024-10-10 |
Family
ID=78622127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023520379A Pending JP2023545983A (ja) | 2020-10-07 | 2021-10-05 | リンパ系悪性腫瘍状態の二重特異性抗体治療 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230365681A1 (https=) |
| EP (1) | EP4225793A1 (https=) |
| JP (1) | JP2023545983A (https=) |
| KR (1) | KR20230083300A (https=) |
| CN (1) | CN116685348A (https=) |
| WO (1) | WO2022076987A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025137576A1 (en) * | 2023-12-22 | 2025-06-26 | Nutcracker Therapeutics, Inc. | Multiple specific antibodies targeting cd19, cd20, and/or cd47 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102338833B1 (ko) | 2012-02-06 | 2021-12-13 | 인히브릭스, 인크. | Cd47 항체 및 그 사용 방법 |
| AU2014227638A1 (en) * | 2013-03-15 | 2015-09-17 | Merck Patent Gmbh | Tetravalent bispecific antibodies |
| HUE046661T2 (hu) * | 2014-08-15 | 2020-03-30 | Merck Patent Gmbh | SIRP-alfa immunglobulin fúziós proteinek |
| WO2016109415A1 (en) | 2014-12-30 | 2016-07-07 | Celgene Corporation | Anti-cd47 antibodies and uses thereof |
| CN109689684B (zh) | 2016-07-06 | 2022-09-23 | 细胞基因公司 | 具有低免疫原性的抗体及其用途 |
| BR112019020185A2 (pt) | 2017-03-27 | 2020-06-02 | Celgene Corporation | Métodos e composições para redução da imunogenicidade |
| WO2019109876A1 (zh) * | 2017-12-04 | 2019-06-13 | 北京韩美药品有限公司 | 抗pd‐l1/抗cd47天然抗体结构样异源二聚体形式双特异抗体及其制备 |
| AU2019218271B2 (en) * | 2018-02-12 | 2024-12-12 | Forty Seven, LLC | Anti-cancer regimen using anti-CD47 and anti-CD20 antibodies |
-
2021
- 2021-10-05 JP JP2023520379A patent/JP2023545983A/ja active Pending
- 2021-10-05 WO PCT/US2021/071718 patent/WO2022076987A1/en not_active Ceased
- 2021-10-05 CN CN202180065527.0A patent/CN116685348A/zh active Pending
- 2021-10-05 KR KR1020237014459A patent/KR20230083300A/ko active Pending
- 2021-10-05 US US18/248,205 patent/US20230365681A1/en active Pending
- 2021-10-05 EP EP21807476.3A patent/EP4225793A1/en active Pending